Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
08:00am, Thursday, 03'rd Nov 2022
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
12:00pm, Monday, 10'th Oct 2022 GlobeNewswire Inc.
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administere
Daré Bioscience to Participate in Two Upcoming Conferences
08:00am, Thursday, 15'th Sep 2022
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and C
Dare Bioscience, Inc. (DARE) CEO Sabrina Johnson on Q2 2022 Results - Earnings Call Transcript
08:35pm, Tuesday, 09'th Aug 2022
Dare Bioscience, Inc. (NASDAQ:DARE ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sabrina Johnson - President, CEO, Secretary & Director John A. Fair - Chief Strateg
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
08:00am, Tuesday, 02'nd Aug 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:3
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
12:00pm, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, wil
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
12:00pm, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Meeting to be reconvened solely with respect to Proposal 5 Meeting to be reconvened solely with respect to Proposal 5
Good Penny Stocks to Buy Now? 3 to Watch in June
07:34pm, Thursday, 02'nd Jun 2022 PennyStocks
Check these penny stocks out for your watchlist right now
The post Good Penny Stocks to Buy Now? 3 to Watch in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Good Penny Stocks to Buy Now? 3 to Watch in June
03:34pm, Thursday, 02'nd Jun 2022
Check these penny stocks out for your watchlist right now The post Good Penny Stocks to Buy Now? 3 to Watch in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
12:00pm, Monday, 16'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President a
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
08:00am, Monday, 16'th May 2022
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO
Dare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call Transcript
08:26pm, Thursday, 12'th May 2022
Dare Bioscience, Inc. (NASDAQ:DARE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief St
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
11:15am, Thursday, 12'th May 2022 Zacks Investment Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
10:00am, Thursday, 12'th May 2022 GlobeNewswire Inc.
Conference Call and Webcast Today at 4:30 p.m. ET
